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M A J O R A R T I C L E
Increase in Methicillin-Resistant Staphylococcus
aureus Acquisition Rate and Change in Pathogen
Pattern Associated with an Outbreak of Severe Acute
Respiratory Syndrome
Florence H. Y. Yap,1 Charles D. Gomersall,1 Kitty S. C. Fung,2 Pak-Leung Ho,3 Oi-Man Ho,1 Phillip K. N. Lam,1
Doris T. C. Lam,1 Donald J. Lyon,2 and Gavin M. Joynt1
Departments of 1Anaesthesia and Intensive Care and 2Microbiology, Prince of Wales Hospital, Chinese University of Hong Kong, and 3Department
of Microbiology and Centre of Infection, Queen Mary Hospital, University of Hong Kong, HKSAR, China
Background. An outbreak of severe acute respiratory syndrome (SARS) occurred in our 22-bed intensive care
unit (ICU; Prince of Wales Hospital, Hong Kong, HKSAR, China) from 12 March to 31 May 2003, when only
patients with SARS were admitted. This period was characterized by the upgrading of infection control precautions,
which included the wearing of gloves and gowns all the time, an extensive use of steroids, and a change in antibiotic
prescribing practices. The pattern of endemic pathogenic organisms, the rates of acquisition of methicillin-resistant
Staphylococcus aureus (MRSA), and the rates of ventilator-associated pneumonia (VAP) were compared with those
of the pre-SARS and post-SARS periods.
Methods. Data on pathogenic isolates were obtained from the microbiology department (Prince of Wales
Hospital). Data on MRSA acquisition and VAP rates were collected prospectively. MRSA screening was performed
for all ICU patients. A case of MRSA carriage was defined as an instance in which MRSA was recovered from any
site in a patient, and cases were classified as imported or ICU-acquired if the first MRSA isolate was recovered
within 72 h of ICU admission or after 72 h in the ICU, respectively.
Results. During the SARS period in the ICU, there was an increase in the rate of isolation of MRSA and
Stenotrophomonas and Candida species but a disappearance of Pseudomonas and Klebsiella species. The MRSA
acquisition rate was also increased: it was 3.53% (3.53 cases per 100 admissions) during the pre-SARS period,
25.30% during the SARS period, and 2.21% during the post-SARS period ( ). The VAP rate was high, atP ! .001
36.5 episodes per 1000 ventilator-days, and 47% of episodes were caused by MRSA.
Conclusions. A SARS outbreak in the ICU led to changes in the pathogen pattern and the MRSA acquisition
rate. The data suggest that MRSA cross-transmission may be increased if gloves and gowns are worn all the time.
Severe acute respiratory syndrome (SARS) is caused by
a novel SARS-associated coronavirus (SARS-CoV) [1].
The SARS epidemic started in November 2002 in the
Guangdong province in China and, within a few
months, had spread rapidly around the world, includ-
ing to Hong Kong [2]. A striking feature of SARS is
its high rate of nosocomial transmission [3] and the
high proportion of young patients that can become
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critically ill. There was a SARS outbreak in our insti-
tution, Prince of Wales Hospital (Hong Kong, HKSAR,
China), in March 2003 [4], as a result of which our
intensive care unit (ICU) admitted only patients with
SARS from 12 March until 31 May 2003.
During the SARS period in the ICU, the patient dem-
ographics, disease pattern, use of antibiotics, and in-
fection control procedures were all different from those
of the pre-SARS and post-SARS periods. Infection con-
trol measures, in particular, were upgraded, including
use of enhanced personal protective equipment (PPE)
and more rigorous environment cleansing and disin-
fection. Infection control measures placed heavy em-
phasis on use of PPE because of the high rate of trans-
mission of SARS to health care workers. Routinely used
PPE included N95 respirators; face shields; caps; long-
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sleeved, disposable gowns; and gloves [5]. For high-risk pro-
cedures, such as intubation and resuscitation, goggles were also
used. We adopted a policy of “always gloving” and “always
gowning”; that is, gloves and gowns were worn all the time in
the ICU, even when there was no direct patient contact. Our
standard hand-hygiene practices included hand-washing with
chlorhexidine and alcoholic hand rub. We postulated that these
changes might result in a change in the pattern of pathogenic
isolates, the rate of methicillin-resistant Staphylococcus aureus
(MRSA) acquisition, and the rate of ventilator-associated pneu-
monia (VAP).
METHODS
Setting. The Prince of Wales Hospital in Hong Kong is a
tertiary-care university teaching hospital with 1500 beds, and
our 22-bed ICU is a mixed medical-surgical ICU. For the pur-
pose of this study, the SARS period was defined as 12 March
through 31 May 2003, the pre-SARS period as January 2001
through February 2003, and the post-SARS period as June 2003
through December 2003. During the SARS period, only patients
with SARS were admitted to the ICU. APACHE II [6] scores
were prospectively determined at admission for all patients.
APACHE II scores range from 0–71, with higher scores indi-
cating more-severe illness and predicting an increased likeli-
hood of death.
MRSA importation and acquisition rates. MRSA is en-
demic in our ICU and accounted for almost 75% of all the
Staphylococcus aureus isolates in the ICU in 2002. Patients col-
onized or infected with MRSA represent the reservoir for cross-
transmission, and ICU acquisition rates were usually positively
correlated with ICU importation rates [7]. An MRSA control
program was implemented in 2000, whereby all patients with
MRSA carriage would be isolated or cohorted, and strict stan-
dard precautions were taken to prevent spread of MRSA. As
part of the MRSA control program, nasal swab specimens were
obtained from all ICU patients to screen for MRSA carriage at
the time of ICU admission, then weekly, and finally upon dis-
charge from the ICU. A case of MRSA carriage was defined as
an instance in which MRSA was recovered from a patient re-
gardless of the site of and type of specimen (i.e., a screening
or clinical diagnostic specimen), or whether the patient was
colonized or infected with MRSA. A case of MRSA carriage
was further classified as imported, if the first MRSA isolate
from any site was recovered within 72 h after ICU admission,
or as ICU-acquired if the first MRSA isolate was recovered after
72 h in the ICU. The number of imported and of ICU-acquired
cases has been prospectively determined as part of our infection
control audit since 2000. MRSA importation rates and MRSA
ICU-acquisition rates were calculated as the total number of
imported or ICU-acquired cases divided by the total number
of ICU admissions over the same time period, respectively [8].
These 2 rates were also compared using patient-days as the
denominator to adjust for differences in the length of stay in
the ICU.
VAP during the SARS period. During the SARS period,
data on VAP were collected as part of our infection control
audit. We followed the model of infection surveillance devel-
oped by the National Nosocomial Infection Surveillance
(NNIS) system, Centers for Disease Control and Prevention
(CDC; Atlanta, GA) [9, 10]. The following data were collected
daily by a dedicated team of doctors and nurses: number of
new ICU admissions, total number of ICU patients, number
of intubated patients, and number of new episodes of VAP and
the causative organisms. These data were compared against
NNIS system data [11] because VAP data for the immediate
pre-SARS and post-SARS periods were not available.
Pathogenic microbial culture rates. The data for the pe-
riod 2001–2003 were obtained from the database of our mi-
crobiology department (Prince of Wales Hospital, Hong Kong).
The most prevalent and important pathogenic organisms in
the ICU were selected (i.e., MRSA; Enterococcus, Candida, Aci-
netobacter, and Enterobacter species; Escherichia coli; and Kleb-
siella, Pseudomonas, and Stenotrophomonas species). Data on
organisms that are often nonpathogenic or are infrequently
recovered are not presented. If 2 or more isolates belonging to
a single species of organism were recovered from the same
patient, they were counted as 1 isolate, and the first or earliest
site from which that isolate was cultured was defined as the
source of the isolate. Both isolates that were imported or ac-
quired in the ICU were included.
Antibiotic use rates. The data on the amounts of anti-
microbials used in 2001–2003 were obtained from the hospital
pharmacy, and only data on antibiotics that are commonly used
in the ICU were selected and analyzed. Antimicrobial use rates
were calculated and compared according to the method de-
scribed by Project ICARE (Intensive Care Antimicrobial Re-
sistance Epidemiology), which was developed by the CDC’s
Hospital Infections Program [12]. A defined daily dose (DDD)
is the typical number of grams of an antimicrobial used per
day for a typical adult patient. Antimicrobial use rates (or DDD
rates) are defined as the number of DDDs per 1000 patient-
days.
Statistical analysis. Statistical analysis was performed us-
ing SPSS software, version 10.0 (SPSS). Continuous variables
were compared using the Student’s t test. Categorical variables
were compared using the x2 test and the Fisher’s exact test.
When comparing rates per patient-days, 95% CIs around pro-
portions were estimated. A P value (2-tailed) of !.05 was con-
sidered significant.
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Figure 1. Methicillin-resistant Staphylococcus aureus (MRSA) importation rates and acquisition rates (calculated as cases per 100 admissions)
associated with an outbreak of severe acute respiratory syndrome in an intensive care unit (ICU) from January 2001 through December 2003.
Table 1. Rates of importation and ICU acquisition of methicillin-resistant Staphylococcus aureus (MRSA) before,




MRSA importation, cases per 100 admissions 5.34 2.41b 2.90 .012
MRSA acquisition, cases per 100 admissions 3.53 25.30c 2.21 !.001
MRSA acquisition, cases per 1000 patient-days (95% CI) 8.7 (7.3–10.4) 16.9c (11.1–25.7) 4.4 (2.7–7.1) NC
NOTE. NC, noncalculable.
a P values are comparisons across the 3 time periods.
b Significantly different from pre-SARS values.
c Significantly different from pre- and post-SARS values.
RESULTS
Patient population. During the SARS period, we had a total
of 83 admissions to the ICU. The median length of an ICU
stay was 10.0 days, with an interquartile range (IQR) of 5.5–
23.5 days. The median APACHE II score was 16 (IQR, 11–22)
during the pre-SARS period, 10 (IQR, 8–13) during the SARS
period, and 15 (IQR, 10–22) during the post-SARS period. All
patients with SARS received ribavirin and high-dose pulse ster-
oids [13]. The median total dose of methylprednisolone re-
ceived per patient during an ICU stay was 2.71 g (IQR, 1.01–
4.17 g).
MRSA importation and acquisition rates. Figure 1 shows
the rates of MRSA importation and ICU acquisition (cases per
100 admissions) from January 2001 through December 2003.
During the SARS period, there were 2 imported cases and 21
ICU-acquired cases of MRSA acquisition. The MRSA impor-
tation rate during the SARS period was lower than that of the
pre-SARS period but similar to that of the post-SARS period.
However, there was a significant increase in the rate of MRSA
ICU acquisition during the SARS period, regardless of whether
the rate was calculated as cases per 100 patient admissions or
cases per 1000 patient-days (table 1).
VAP during the SARS period. There were 30 episodes of
VAP in 22 patients, for a rate of 36.5 episodes per 1000 ven-
tilator-days. This is much higher than the 90th percentile dis-
tribution for medical ICUs (9.6 episodes per 1000 ventilator-
days) or medical-surgical ICUs in major teaching hospital (12.1
per 1000 ventilator-days) in the NNIS system [11]. Most of the
organisms causing VAP were MRSA (47.1% of isolates), fol-
lowed by Stenotrophomonas species (29.4%) and Acinetobacter
species (14.7%).
Pathogenic microbial culture rates. Figure 2 shows the
frequency and distribution of the main pathogenic organisms
in terms of the number of nonduplicate isolates per 100 patient
admissions. These isolates included those imported into the
ICU and those acquired after admission to the ICU. During
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Figure 2. Rate of isolation of pathogens from culture before, during, and after an outbreak of severe acute respiratory syndrome (SARS) in an
intensive care unit (ICU). *Significantly different during the SARS period, compared with the pre-and post-SARS periods.
Table 2. The body sites from which the selected main patho-
gens were cultured.
Body site










Respiratory tract 930 (50.2) 40 (46.5) 222 (53.0)
Urinary tract 214 (11.6) 9 (10.5) 66 (15.8)
Blood 199 (10.7) 11 (12.8) 42 (10.0)
Abdomen 60 (3.2) 3 (3.5) 14 (3.3)
Other 450 (24.3) 23 (26.7) 75 (17.9)
the SARS period, there was a significant increase in the fre-
quency of isolation of MRSA, Stenotrophomonas species, and
Candida species and a significant decrease in the frequency of
isolation of Pseudomonas and Klebsiella species. Table 2 shows
the body sites from which these organisms were cultured. There
were no differences among the 3 time periods, pre-SARS, SARS,
and post-SARS.
Antibiotic use rates. Figure 3 showed the use rates (DDDs
per 1000 patient-days) of the common antibiotics used in the
ICU. During the SARS period, there was a marked increase in
total antibiotic use, as well as an increase in the use of cefepime,
carbapenams, fluoroquinolones, aminoglycosides, and vanco-
mycin.
DISCUSSION
Our data demonstrated that changes in the case mix of patients,
infection control measures, and antibiotic prescribing practices
in an ICU during a SARS outbreak could result in major
changes in the rates of cross-transmission of MRSA and the
pattern of prevalent pathogenic microbes. The increase in ac-
quisition of MRSA and Candida species is a serious concern
because of the high morbidity and mortality and the limited
therapeutic options associated with infection with these organ-
isms [14–16]. Among the gram-negative isolates, there was an
increase of Stenotrophomonas species and a disappearance of
Pseudomonas and Klebsiella species. The data are of importance
because they suggest that microbiological surveillance may be
necessary after instituting changes in the ICU so that appro-
priate empirical antibiotic treatment can be chosen.
One important finding of our study is that the frequency of
acquisition of MRSA in the ICU was significantly increased
despite upgraded infection control measures and a low im-
portation rate of MRSA into the ICU. There are a number of
plausible explanations. First, this could be related to our in-
fection control policy. During the SARS period, all patients in
the ICU were patients with SARS, and the whole ICU was
considered to be a high-risk area. The practice of wearing gloves
and gowns all the time was introduced at that time with the
intention of maximizing staff protection. Although staff were
advised to change gloves and cleanse hands before and after
each contact with a patient and between dirty body-site and
clean body-site care for the same patient, excessive use of gloves,
especially worn together with the long-sleeved gowns, could
have contributed to low compliance with this policy. In fact,
poor compliance with hand hygiene has been identified among
glove users in previous studies [17–19]. This could result in
direct cross-transmission of MRSA between patients and also
heavy contamination of the ICU environment (e.g., the nursing
station, the radiograph viewing room, and other non–patient-
care areas), leading to an increase in MRSA acquisition in the
ICU. The routine wearing of long-sleeved gowns, which were
not changed between contacts with patients, could also have
contributed to cross-transmission of MRSA [20]. During the
post-SARS period, when the routine wearing of gloves and
gowns was abandoned, the MRSA acquisition rate decreased
again to the pre-SARS level.
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Figure 3. Antibiotic use rates (calculated as defined daily doses [DDDs] per 1000 patient-days) of the selected commonly used antibiotics in the
intensive care unit (ICU) before, during, and after an outbreak of severe acute respiratory syndrome (SARS). *Significantly increased during the SARS
period, compared with the pre- and post-SARS periods. The ampicillin group includes amoxicillin/clavulanate, ampicillin/sulbactam, and ampicillin. The
antipseudomonal penicillin group includes piperacillin and piperacillin/tazobactam. The third-generation cephalosporin group includes ceftazidime,
cefotaxime, ceftriazone, and cefoperazone/sulbactam. The carbapenam group includes imipenam/cilastatin and meropenam. The quinolone group includes
ciprofloxacin and levofloxacin. The aminoglycoside group includes netilmicin, amikan, and gentamycin.
Another reason for the increase in MRSA aquisition during
the SARS period could be the heavy use of antimicrobials active
against gram-negative organisms. This, and the heavy use of
steroids, could also have contributed to the overgrowth of both
MRSA and Candida species. It has also been suggested that
fluoroquinolone use is a risk factor in selecting for MRSA car-
riage [21] and infection [22], and the use of fluoroquinolones
in our ICU was significantly increased during the SARS period.
The third plausible mechanism might be related to SARS-
CoV. The VAP rate was high during the SARS period, and about
half of all episodes were caused by MRSA. It is known that
influenza increases the risk of secondary infection by S. aureus
[23, 24]. Since SARS-CoV is a respiratory virus, it is possible
that SARS may also predispose patients to secondary infection
by S. aureus. The molecular mechanism for this is uncertain.
The eradication of Pseudomonas species during the SARS
outbreak is noteworthy because they were important pathogens
in the ICU before and after the SARS period. Although changes
in respiratory-care practices and environment disinfection dur-
ing the SARS period could have contributed to this phenom-
enon, most of these practices continued into the post-SARS
period, when Pseudomonas species were again prevalent, and,
therefore, were unlikely to be important causative factors. How-
ever, the heavy use of cefepime during the SARS period, a drug
that is otherwise rarely used and to which most Pseudomonas
species would be presumed to be sensitive because of previous
nonexposure, might be a contributing factor.
In summary, we have shown that changes in an ICU during
a SARS outbreak may be associated with a significant change
in the pattern of endemic pathogens. The data also suggest that
cross-transmission of MRSA may be increased, despite up-
graded infection control measures, if the measures included
excessive use of gloves and gowns.
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